BillionToOne (BLLN) Q4 2025 earnings review
Hyper-Growth Maintained, But Pricing Did the Heavy Lifting
BillionToOne delivered an exceptional Q4, completely ignoring its own prior warnings about historical Q4 seasonality. Total revenue surged 113% year-over-year to $96.1 million, while GAAP operating margins stabilized at a healthy 11%. The company reversed its trajectory from heavy cash burn to sustainable profitability, ending the year with $496 million in the bank. However, investors must look under the hood: the massive revenue beat was driven almost entirely by a structural spike in pricing (ASP), while sequential volume growth slowed to a crawl. Management confidently raised FY26 guidance, forecasting up to $445 million in revenue.
🐂 Bull Case
Gross margins expanded 14 percentage points year-over-year to 71%, proving the QCT platform scales beautifully. The company flipped a $47 million operating loss in 2024 into a $16 million operating profit in 2025.
The oncology segment is accelerating violently, up 735% year-over-year in Q4 to $9.1 million. It has transformed from a rounding error to a material growth engine.
🐻 Bear Case
Quarter-over-quarter test volume grew a mere 3% (165,000 to 170,000). The 15% sequential revenue jump was fueled entirely by ASP expanding from $501 to $561. This pricing leverage is finite.
Base effects are catching up. After delivering 100% top-line growth in FY25, FY26 guidance implies deceleration to 41-46% growth. Any execution misstep could trigger a multiple contraction.
⚖️ Verdict: 🟢
Bullish. Achieving 113% growth while turning GAAP profitable is incredibly rare in molecular diagnostics. While the sequential volume slowdown is a legitimate concern, the sheer pricing power and cash generation make this a premium asset.
Key Themes
The Real Story: Unprecedented Pricing Power
Accelerating. BillionToOne's overall Average Selling Price (ASP) exploded to $561 in Q4, up 47% YoY and a massive sequential jump from $501 in Q3. This is the structural result of expanded commercial payer coverage (now 235 million lives) and Medicaid adoption of higher-value PLA codes for the UNITY Carrier panel. This pricing power, not unit volume, is the primary driver of the company's sudden shift to profitability.
Oncology Becomes a Legitimate Pillar
Accelerating. Oncology clinical testing revenue hit $9.1 million in Q4, up more than 8x from $1.1 million a year ago. Management's thesis that the Northstar platform's superior sensitivity (finding 51% more SMVs) would win market share is being validated by the numbers. The ~2:1 recurring usage ratio of Response to Select tests is creating a compounding revenue snowball.
Operating Leverage Reaches Inflection Point
Reversing. The company has officially escaped the cash-burn phase. Gross margins hit a record 71% in Q4 (up from 57% YoY). Operating margin remained stable at 11% sequentially. With only ~25% of lab capacity currently utilized, the cost-per-test economics have significant room to improve as volumes scale, locking in long-term GAAP profitability.
Relentless Product Innovation
The company continues to expand its addressable market through rapid R&D. In Q1 2026, it launched the Red Blood Cell and Platelet Fetal Antigen NIPTs—the first and only non-invasive tests in the US for Hemolytic Disease of the Fetus and Newborn (HDFN). Simultaneously, they launched Northstar PGx and Northstar Select CH for oncology, moving the platform beyond pure genomic profiling into chemotherapy safety.
Volume Growth is Stalling
Decelerating. A major red flag hidden in the blowout revenue numbers is test volume. The company delivered 170,000 tests in Q4, compared to 165,000 in Q3. That is a sequential volume growth of only 3%. If the recent ASP tailwinds (Medicaid PLA code adoption) normalize, the company will need to prove it can re-accelerate raw unit demand to hit its aggressive 2026 targets.
Oncology Margin Dilution Risk
While oncology growth is spectacular, management flagged in Q3 that it carries a lower gross margin profile than the legacy prenatal business. As oncology becomes a larger percentage of total revenue (now nearly 10%), it will mathematically drag down the corporate gross margin average unless cost-per-test drops dramatically in the cancer segment.
Execution Risk on Strategic Milestones
The massive health system total addressable market (TAM) unlock relies heavily on the integration with Epic EMR, a complex IT project flagged in Q3 as taking up to 9 months. Additionally, the next leg of oncology growth depends on securing Medicare MolDX coverage for Northstar Response by late 2026. Both are binary execution risks that are currently un-secured.
Other KPIs
A fortress balance sheet. Following the November 2025 IPO which netted ~$286 million, the company sits on nearly half a billion in cash. Importantly, the core business generated positive operating cash flow of $8.8 million in Q4, meaning the IPO capital is pure growth fuel rather than survival funding.
Operating expenses grew 50% YoY, roughly half the pace of total revenue growth (100%). This disciplined SG&A and R&D spending demonstrates management's commitment to profitable growth, rather than buying revenue at any cost.
Guidance
Decelerating in percentage terms, but accelerating in absolute dollars. Management raised this from the prior $415-$430M range. The midpoint implies 43.5% YoY growth, a step down from the 100% YoY growth seen in FY25, reflecting the law of large numbers. However, it still adds roughly $132 million in new revenue.
Stable. The company explicitly guided to maintaining positive GAAP operating income for the full year 2026, confirming that the back half of 2025 was a structural inflection point, not a one-time anomaly.
Key Questions
The ASP Ceiling
ASP jumped from $501 in Q3 to $561 in Q4. How much of this was a one-time true-up or immediate step-function from Medicaid codes, versus a trend that can continue? Where do you view the theoretical ceiling for blended ASP?
Sequential Volume Softness
Test volumes grew only 3% quarter-over-quarter. While Q4 is historically seasonal, with 8-10 new prenatal reps added per quarter, why didn't we see stronger unit growth? Are you hitting penetration limits in your current geographic footprints?
Oncology Margin Roadmap
With Oncology growing 700%+ YoY, it will soon become a material drag on the 71% gross margin if unit economics don't improve. What is the specific timeline and COGS roadmap for bringing oncology margins to parity with prenatal?